A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

Summary

The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the ABCA4 gene. The study will also assess initial efficacy following AAVB-039 administration.

Timeline

Start

2025-09-29

Primary completion

2032-07

Completion

2032-07

Drugs

Indications